Ultrasound Guided Fine-Needle Aspiration Biopsy Proves 100% Accurate in 166 Women

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

A study of 166 women with suspicious mammograms who underwent ultrasound-guided fine-needle aspiration cytology (USFNAC) showed the technique to be 100% accurate in diagnosing cancers, reported Dr. Thomas G. Frazier at the annual

A study of 166 women with suspicious mammograms who underwentultrasound-guided fine-needle aspiration cytology (USFNAC) showedthe technique to be 100% accurate in diagnosing cancers, reportedDr. Thomas G. Frazier at the annual meeting of the American RadiumSociety, held in Paris, France. This number is based on 3-monthfollow-up of the patients, said Dr. Frazier, who is Senior AttendingSurgeon at the Bryn Mawr Hospital in Bryn Mawr, Pennsylvania,

"We found 17 early cancers in our study (none could be felt),"said Dr. Frazier, who is also Clinical Professor of Surgery atthe Medical College of Pennsylvania. "In our study, the costto diagnose each cancer was $4,667 when USFNAC was used. Thiscompares to $52,505 per cancer diagnosed for standard biopsy procedures.That's more than a 91% savings," he commented.

"We looked at the costs of biopsy alone by averaging thecosts of five patients and found that standard biopsies cost about$5,377. This compares to USFNAC, which costs only $478 per procedure,"he said.

Recent Videos
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Two experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
7 experts are featured in this series.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Related Content